Searcharxiv⌕ Search

arXiv subjects

Bobbi Fleiss

Publications and source records attributed to Bobbi Fleiss.

3 recordsLinked to original sources

A passive, battery-free flexible metasurface for implantable millimetre-wave radar glucose sensing

Continuous glucose monitors (CGM) break the skin barrier and require periodic sensor replacement. We investigated whether a passive, battery-free flexible metasurface, implanted beneath tissue and read by a commercial 60 GHz radar, can track blood glucose levels. The metasurface contained no electronics or reagents. We fitted a conical helix to the in-phase and quadrature radar signals across the frequency sweep and used its mean radius (the spiral radius) as the glucose-dependent feature. We tested glucose concentrations of 25 to 400 mg/dL in saline solution with and without the metasurface, and 196 to 596 mg/dL of total glucose in porcine whole blood beneath ex vivo porcine tissue and in a murine cadaver model with pulsatile blood flow. The metasurface was essential for achieving a monotonic sensor response; in saline, the coefficient of determination ($R^2$) of a logarithmic fit increased from 0.18 without the metasurface to 0.90 with it. In a murine (rat) cadaver model, the signal's spiral radius increased monotonically with glucose concentration despite pulsatile flow ($R^2$ = 0.91), and this monotonic behavior persisted through up to 6 mm of tissue. Although sensitivity decreased at higher glucose levels, each discrete concentration step remained clearly detectable. These results demonstrate that a shallow, passive implant paired with a commercial radar can effectively track blood glucose without requiring onboard electronics or batteries.

physics.bio-ph↗

Exogeneous PpIX model for brain tumour assessment

Reliable in-vitro models are used for optoelectronic device development such as fluorescence detection devices for fluorescence-guided surgery of gliomas. A common approach is based on inducing gliomas in animal models. This is followed by a dosage of 5-ALA to induce Protoporphyrin IX (PpIX) in the glioma and which fluoresces. Although these approaches excel in capturing key biomolecular and physiological features of the tumour, they are inherently indeterministic. This limits the scope of their use for preclinical device development, where consistent and controllable tumour reproduction across multiple animals is needed. Approaches using fluorescence markers in gelatine provide a simple replication but fail to capture the complexities of in-vivo models. In this study, we introduce an exogenous brain tumour model for assessing PpIX fluorescence detection. The model was developed by injecting a PpIX solution into the cortical region of a resected adult rat brain, the injection site simulated a tumoral region with elevated PpIX concentration. The tumoral region had a gradient of concentrations, with a peak at the centre and a decrease towards the margins, akin to in-vivo gliomas. The fluorescence profile was compared to in-vivo conditions using 5-ALA and correlated well with other reported works, achieving a correlation of R2>0.93. The model's validity was tested by examining the effect of the solvent, DMSO, on the Autofluorescence (AF) of the brain sample and the short-term effect of storage on AF was analysed. Examinations confirmed the solvent did not alter AF, and the brain sample should be stored in Hanks Balanced Salt Solution and refrigerated to maintain moisture and preserve AF. The model accurately replicated surgical fluorescence conditions and offers a suitable alternative to glioma induction, benefiting the development of fluorescence detection devices across design iterations.

physics.bio-ph↗

Miniature fluorescence sensor for quantitative detection of brain tumour

Fluorescence-guided surgery has emerged as a vital tool for tumour resection procedures. As well as intraoperative tumour visualisation, 5-ALA-induced PpIX provides an avenue for quantitative tumour identification based on ratiometric fluorescence measurement. To this end, fluorescence imaging and fibre-based probes have enabled more precise demarcation between the cancerous and healthy tissues. These sensing approaches, which rely on collecting the fluorescence light from the tumour resection site and its remote spectral sensing, introduce challenges associated with optical losses. In this work, we demonstrate the viability of tumour detection at the resection site using a miniature fluorescence measurement system. Unlike the current bulky systems, which necessitate remote measurement, we have adopted a millimetre-sized spectral sensor chip for quantitative fluorescence measurements. A reliable measurement at the resection site requires a stable optical window between the tissue and the optoelectronic system. This is achieved using an antifouling diamond window, which provides stable optical transparency. The system achieved a sensitivity of 92.3% and specificity of 98.3% in detecting a surrogate tumour at a resolution of 1 x 1 mm2. As well as addressing losses associated with collecting and coupling fluorescence light in the current remote sensing approaches, the small size of the system introduced in this work paves the way for its direct integration with the tumour resection tools with the aim of more accurate interoperative tumour identification.

eess.SY↗